BioCentury
ARTICLE | Clinical News

Cel-Sci preclinical data

September 15, 2008 7:00 AM UTC

In a mouse model of RA, CEL-2000 was as good as Enbrel etanercept in slowing disease progression. Amgen Inc. (NASDAQ:AMGN, Thousand Oaks, Calif.) co-markets Enbrel in the U.S. and Canada with Wyeth...